Antibody-drug conjugate · Kills target cells, directed at HER2 (ERBB2) (ERBB2) · developed by RemeGen Co.
Phase 1/2Most advanced trial
What is Disitamab Vedotin?
Disitamab vedotin is an antibody-drug conjugate in which a humanized IgG1 antibody against HER2 is linked to the microtubule-disrupting agent MMAE. After binding HER2 on tumor cells and internalization, the released MMAE inhibits microtubule polymerization, causing cell cycle arrest and apoptosis. It is studied in breast cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
RC48, RC48-ADC
Drug type
Antibody-drug conjugate
Targets
HER2 (ERBB2) (ERBB2), tubulin (secondary target)
Mechanism
Kills target cells, directed at HER2 (ERBB2) (ERBB2)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.